Evidence map›Paper›PMID 35278242›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2022

Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.

Tori Kroon, Neharika Bhadouria, Paul Niziolek, Daniel Edwards, Roy Choi, Erica L Clinkenbeard, Alexander Robling, Nilsson Holguin

Open access · greenAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tori KroonDepartment of Biomedical Engineering, IUPUI, Indianapolis, IN, USA.
Neharika BhadouriaDepartment of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Paul NiziolekRadiology & Imaging Sciences, IUPUI, Indianapolis, IN, USA.
Daniel EdwardsIndiana Center of Musculoskeletal Health, Indianapolis, IN, USA.
Roy ChoiDepartment for Anatomy and Cell Biology, IUPUI, Indianapolis, IN, USA.
Erica L ClinkenbeardIndiana Center of Musculoskeletal Health, Indianapolis, IN, USA.ORCID 0000-0001-6687-1106
Alexander RoblingIndiana Center of Musculoskeletal Health, Indianapolis, IN, USA.ORCID 0000-0002-3989-4780
Nilsson HolguinIndiana Center of Musculoskeletal Health, Indianapolis, IN, USA.ORCID 0000-0001-8446-845X
Indiana University Health · USIndiana University – Purdue University Indianapolis · USPurdue University West Lafayette · US

Funding

Biomechanics and Biomaterials Research Center grantBiomedical Research GrantStart-Up from Mechanical and Energy Engineering, IUPUIWashington University in St. Louis
6 · The paper itself

Abstract

Intervertebral disc (IVD) degeneration is a leading cause of low back pain, characterized by accelerated extracellular matrix breakdown and IVD height loss, but there is no approved pharmacological therapeutic. Deletion of Wnt ligand competitor Lrp5 induces IVD degeneration, suggesting that Wnt signaling is essential for IVD homeostasis. Therefore, the IVD may respond to neutralization of Wnt ligand competitors sost(gene)/sclerostin(protein) and/or dickkopf-1 (dkk1). Anti-sclerostin antibody (scl-Ab) is an FDA-approved bone therapeutic that activates Wnt signaling. We aimed to (i) determine if pharmacological neutralization of sclerostin, dkk1, or their combination would stimulate Wnt signaling and augment IVD structure and (ii) determine the prolonged adaptation of the IVD to global, persistent deletion of sost. Nine-week-old C57Bl/6J female mice (n = 6-7/group) were subcutaneously injected 2×/week for 5.5 weeks with scl-Ab (25 mg/kg), dkk1-Ab (25 mg/kg), 3:1 scl-Ab/dkk1-Ab (18.75:6.25 mg/kg), or vehicle (veh). Separately, IVD of sost KO and wild-type (WT) mice (n = 8/group) were harvested at 16 weeks of age. First, compared with vehicle, injection of scl-Ab, dkk1-Ab, and 3:1 scl-Ab/dkk1-Ab similarly increased lumbar IVD height and β-catenin gene expression. Despite these similarities, only injection of scl-Ab alone strengthened IVD mechanical properties and decreased heat shock protein gene expressions. Genetically and compared with WT, sost KO enlarged IVD height, increased proteoglycan staining, and imbibed IVD hydration. Notably, persistent deletion of sost was compensated by upregulation of dkk1, which consequently reduced the cell nuclear fraction for Wnt signaling co-transcription factor β-catenin in the IVD. Lastly, RNA-sequencing pathway analysis confirmed the compensatory suppression of Wnt signaling and revealed a reduction of cellular stress-related pathways. Together, suppression of sost/sclerostin or dkk1 each augmented IVD structure by stimulating Wnt signaling, but scl-Ab outperformed dkk1-Ab in strengthening the IVD. Ultimately, postmenopausal women prescribed scl-Ab injections to prevent vertebral fracture may also benefit from a restoration of IVD height and health. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Indexed as

Adaptor Proteins, Signal TransducingIntercellular Signaling Peptides and ProteinsIntervertebral DiscAnimalsAntibodiesbeta CateninFemaleHumansLigandsMiceMice, Inbred C57BLWnt Signaling PathwayAdaptor Proteins, Signal TransducingAntibodiesbeta CateninDkk1 protein, mouseIntercellular Signaling Peptides and ProteinsLigandsSost protein, mouseANABOLIC THERAPEUTICSCHONDROCYTE AND CARTILAGE BIOLOGYGENETIC ANIMAL MODELSPRECLINICAL STUDIESWNT/β-CATENIN/LRPs

Identifiers

PMID35278242
PMCPMC9320845
OpenAlexW4221042923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.